Reuters
27 Jul 2026, 05:15 UTC · 2h ago
Argenx to buy Forte Biosciences for about $2.2 billion
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
27 Jul 2026, 05:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
argenx is acquiring Forte Biosciences to obtain the experimental autoimmune drug FB102. — Acquisitions of promising drug candidates typically expand a biotech's pipeline and potential future revenue streams.
+0.40Which stocks this story touches
The company is being acquired, typically providing a premium for shareholders.
Expanding its portfolio through the acquisition of a new experimental autoimmune drug.
Continue reading
6 related stories
Search tags
[a_to_b] argenx announced it will buy Forte Biosciences to add the drug FB102 to its portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
12h ago
